EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

John Mascarenhas, Claire Harrison, Tammy A Schuler, Djibril Liassou, Marné Garretson, Taavy A Miller, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S DeGutis, Pranav Abraham, Jonathan Kish und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.09.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von John Mascarenhas und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.mascarenhas@mssm.edu. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Nitriles, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisNitrilesPyrazolesPyrimidinesAdultHumansMaleMiddle AgedAgedAged, 80 and overFemaleRetrospective StudiesProtein Kinase InhibitorsPyrrolidinesSulfonamides

Stichwörter der Autor:innen

Janus kinase 2 inhibitorMyeloproliferative neoplasmsReal-world data

Substanzen

ruxolitinibProtein Kinase InhibitorsPyrrolidinesSulfonamidesNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.mascarenhas@mssm.edu.
  • Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Cardinal Health, Dublin, OH.
  • Bristol Myers Squibb, Princeton, NJ.
  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Mascarenhas, J., Harrison, C., Schuler, T. A., Liassou, D., Garretson, M., Miller, T. A., Mahadevan, S., McBride, A., Tang, D., DeGutis, I. S., Abraham, P., Kish, J., Feinberg, B. A., & Gerds, A. T. (2024). Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.09.008

Vancouver

Mascarenhas J, Harrison C, Schuler TA, Liassou D, Garretson M, Miller TA, et al. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.09.008

BibTeX
@article{Mascarenhas2024,
  author = {Mascarenhas, John and Harrison, Claire and Schuler, Tammy A and Liassou, Djibril and Garretson, Marné and Miller, Taavy A and Mahadevan, Sankar and McBride, Ali and Tang, Derek and DeGutis, Irene S and Abraham, Pranav and Kish, Jonathan and Feinberg, Bruce A and Gerds, Aaron T},
  title = {Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.09.008}
}
Kostenlos starten →